BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 25609157)

  • 1. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.
    Bonfá AC; Seguro LP; Caparbo V; Bonfá E; Pereira RM
    Osteoporos Int; 2015 May; 26(5):1563-71. PubMed ID: 25609157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
    Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene-gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women.
    Zupan J; Mencej-Bedrac S; Jurković-Mlakar S; Prezelj J; Marc J
    J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):102-6. PubMed ID: 19896533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Polymorphism of osteoprotegerin gene and osteoporosis in postmenopausal women].
    Seremak-Mrozikiewicz A; Tatuśko J; Drews K; Barlik M; Krajewski P; Spaczyński M; Mrozikiewicz PM
    Ginekol Pol; 2009 May; 80(5):354-60. PubMed ID: 19548455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms.
    Eid R; Abdelsalam M; Fathy AA; Abolenein HM; Elmarghany EB; El-Hanafy AA; Hamdy N; Abd-Elmagid DS; Niazy NA; Abd-El Ghaffar DM
    Pediatr Rheumatol Online J; 2023 Jun; 21(1):58. PubMed ID: 37328895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allelic variations of RANKL/OPG signaling system are related to bone mineral density and in vivo gene expression.
    Takács I; Lazáry A; Kósa JP; Kiss J; Balla B; Nagy Z; Bácsi K; Speer G; Lakatos P
    Eur J Endocrinol; 2010 Feb; 162(2):423-31. PubMed ID: 19934266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men.
    Hsu YH; Niu T; Terwedow HA; Xu X; Feng Y; Li Z; Brain JD; Rosen CJ; Laird N; Xu X
    Hum Genet; 2006 Jan; 118(5):568-77. PubMed ID: 16249885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).
    Kim HR; Lee SH; Kim HY
    Rheumatology (Oxford); 2006 Oct; 45(10):1197-200. PubMed ID: 16567356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
    Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between osteoprotegerin gene polymorphism and bone mineral density in patients with adolescent idiopathic scoliosis.
    Eun IS; Park WW; Suh KT; Kim JI; Lee JS
    Eur Spine J; 2009 Dec; 18(12):1936-40. PubMed ID: 19705167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures.
    Langdahl BL; Carstens M; Stenkjaer L; Eriksen EF
    J Bone Miner Res; 2002 Jul; 17(7):1245-55. PubMed ID: 12096838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
    Monegal A; Navasa M; Peris P; Alvarez L; Pons F; Rodés J; Guañabens N
    Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
    Mezquita-Raya P; de la Higuera M; García DF; Alonso G; Ruiz-Requena ME; de Dios Luna J; Escobar-Jiménez F; Muñoz-Torres M
    Osteoporos Int; 2005 Nov; 16(11):1368-74. PubMed ID: 15711777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
    Kananen K; Volin L; Laitinen K; Ruutu T; Välimäki MJ
    Osteoporos Int; 2006; 17(5):724-30. PubMed ID: 16437190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
    Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
    Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.
    Zhao HY; Liu JM; Ning G; Zhao YJ; Chen Y; Sun LH; Zhang LZ; Xu MY; Chen JL
    Osteoporos Int; 2008 Feb; 19(2):221-6. PubMed ID: 17703270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
    Shaarawy M; Fathy SA; Mehany NL; Hindy OW
    Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.
    Rouster-Stevens KA; Langman CB; Price HE; Seshadri R; Shore RM; Abbott K; Pachman LM
    Arthritis Rheum; 2007 Mar; 56(3):977-83. PubMed ID: 17328075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.